MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008

Wednesday, February 6, 2008 General News J E 4
GERMANTOWN, Md., Feb. 5 MiddleBrookPharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused ondeveloping and commercializing novel anti-infective products, today announcedthat Dr. Edward M. Rudnic, MiddleBrook president and CEO, will deliver acorporate presentation on Monday, February 11, 2008, at 11:45 a.m. EasternTime.

The presentation will take place as part of the Biotechnology IndustryOrganization (BIO) CEO & Investor Conference 2008 at the Waldorf Astoria hotelin New York, New York. Dr. Rudnic's remarks will be available live on theMiddleBrook web site, where they also will be archived for 30 days.

To access the presentation, log on to and clickon the Presentations option in the Investor Relations section. Please connectto the web site several minutes prior to the start of the live presentation toensure adequate time for any software download that may be necessary.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceuticalcompany focused on the development and commercialization of anti-infectivedrug products that fulfill substantial unmet medical needs in the treatment ofinfectious disease. The Company is developing anti-infective drugs based onits novel biological finding that bacteria exposed to antibiotics in front-loaded staccato bursts, or "pulses," are killed more efficiently andeffectively than those under standard treatment regimens. Based on thisfinding, MiddleBrook has developed a proprietary, once-a-day pulsatiledelivery technology called PULSYS(TM). The Company currently markets theKeflex(R) brand of cephalexin and has received regulatory approval forMOXATAG(TM) -- the first and only once-daily amoxicillin product approved formarketing in the U.S. For more on MiddleBrook, please

SOURCE MiddleBrook Pharmaceuticals


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Novel Small Molecule Therapy Shows Benefit for Ane...
Dr. Richard Merkin & Heritage Victor Valley Medica...